JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Vertebral Body Tethering Treatment for Idiopathic Scoliosis

  NCT03802656

  Conditions:   Scoliosis;   Spinal Curvatures;   Spinal Diseases;   Bone Diseases;   Musculoskeletal Disease;   Adolescent Idiopathic Scoliosis;   Juvenile; Scoliosis
  Intervention:   Device: Anterior Vertebral Body Tethering
  Sponsor:   Lawrence Haber
  Recruiting
• Engaging Seronegative Youth to Optimize HIV Prevention Continuum

  NCT03134833

  Conditions:   HIV;   Mental Health;   Substance Use;   STI
  Interventions:   Behavioral: Automated Messaging & Monitoring;   Behavioral: Peer Support;   Behavioral: Coaching
  Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Tulane University Health Sciences Center;   University of California, San Francisco;   Friends Research Institute, Inc.
  Recruiting
• Stepped Care for Youth Living With HIV

  NCT03109431

  Conditions:   HIV;   Mental Health;   Illicit Substance Use;   Sexually Transmitted Infections (STI)
  Interventions:   Behavioral: Level 1;   Behavioral: Level 2;   Behavioral: Level 3
  Sponsors:   University of California, Los Angeles;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Wake Forest University Health Sciences;   Tulane University Health Sciences Center;   Columbia University
  Recruiting
• The Weaving Healthy Families Program to Promote Wellness and Resilience and Prevent Alcohol and Other Drug Abuse and Violence

  NCT03924167

  Conditions:   Alcohol Abuse;   Drug Use;   Violence, Domestic;   Child Abuse;   Diet Modification;   Health Behavior;   Health Knowledge, Attitudes, Practice;   Relationship, Family;   Relation, Parent-Child;   Emotional Stress
  Intervention:   Behavioral: Weaving Healthy Families Program
  Sponsors:   Tulane University;   National Institutes of Health (NIH)
  Recruiting
• Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers

  NCT03843424

  Condition:   Obesity, Childhood
  Interventions:   Behavioral: eSOC program;   Behavioral: FBT program
  Sponsors:   Washington University School of Medicine;   Patient-Centered Outcomes Research Institute;   Blue Cross Blue Shield of Louisiana;   Louisiana Healthcare Connections;   American Academy of Pediatrics;   Pennington Biomedical Research Center;   University of Rochester
  Recruiting
• The Hemophilia Ultrasound Project

  NCT02807753

  Conditions:   Hemophilia A;   Hemophilia B
  Interventions:   Other: Ankle and Knee Ultrasound Joint Assessment;   Other: Ankle and Knee Magnetic Resonance Imaging
  Sponsors:   University of Miami;   Shire
  Recruiting
• Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

  NCT04029116

  Condition:   Recurrent Vulvovaginal Candidiasis
  Interventions:   Drug: Fluconazole Tablet;   Drug: IBREXAFUNGERP;   Drug: Placebo oral tablet
  Sponsor:   Scynexis, Inc.
  Recruiting
• Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

  NCT03672487

  Condition:   Chagas Disease
  Interventions:   Drug: Benznidazole;   Drug: Placebo Oral Tablet
  Sponsors:   Tulane University School of Public Health and Tropical Medicine;   Institute for Clinical Effectiveness and Health Policy;   University of California, San Diego
  Recruiting
• INdividualized ITI Based on Fviii(ATE) Protection by VWF

  NCT03204539

  Conditions:   Hemophilia A With Inhibitor;   Hemophilia A
  Intervention:   Drug: Wilate
  Sponsor:   University of California, Davis
  Recruiting
• iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

  NCT03815019

  Conditions:   Feeding Behavior;   Feeding Disorder of Infancy or Early Childhood
  Interventions:   Drug: Megestrol Acetate;   Behavioral: iKanEat Behavioral Intervention
  Sponsor:   University of Kansas Medical Center
  Recruiting
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358

  Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

  NCT02369653

  Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
  Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
  Sponsors:   Bristol-Myers Squibb;   Pfizer
  Recruiting
• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
  Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

  NCT03914625

  Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
  Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03698994

  Conditions:   Advanced Malignant Solid Neoplasm;   MAPK1 Gene Mutation;   Recurrent Ependymal Tumor;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Pharmacokinetic Study;   Drug: Ulixertinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582

  Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Elevated Alpha-Fetoprotein;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
  Intervention:   Drug: Olaparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

  NCT03213704

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
  Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

  NCT03213652

  Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
  Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03210714

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

  NCT02847130

  Conditions:   Acute Lymphoblastic Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chemotherapy-Related Nausea and/or Vomiting;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Neoplasm;   Febrile Neutropenia;   Hematopoietic Cell Transplant Recipient;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Other: Informational Intervention;   Other: Interview;   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• STRIDE Biorepository

  NCT02843347

  Condition:   Anemia, Sickle Cell
  Intervention:   Procedure: Blood draw
  Sponsors:   Emory University;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579

  Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
  Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

  NCT02369159

  Condition:   Influenza
  Interventions:   Drug: Peramivir;   Drug: Oseltamivir
  Sponsor:   BioCryst Pharmaceuticals
  Recruiting
• A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

  NCT02803918

  Condition:   Type 2 Diabetes Mellitus
  Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Placebo;   Drug: Basal Insulin;   Drug: Metformin
  Sponsor:   Sanofi
  Recruiting
• A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

  NCT03588975

  Conditions:   Chondral Defect;   Osteochondritis Dissecans;   Articular Cartilage Defect;   Articular Cartilage Disorder of Knee
  Interventions:   Biological: MACI;   Procedure: microfracture
  Sponsor:   Vericel Corporation
  Recruiting
• Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients

  NCT03346083

  Condition:   VTE Prophylaxis
  Intervention:   Drug: Betrixaban
  Sponsor:   Portola Pharmaceuticals
  Recruiting
• Safety of Sildenafil in Premature Infants

  NCT03142568

  Condition:   Bronchopulmonary Dysplasia
  Interventions:   Drug: Sildenafil;   Other: Placebo
  Sponsors:   University of North Carolina, Chapel Hill;   Duke University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The Emmes Company, LLC
  Recruiting
• Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission

  NCT03223753

  Condition:   Acute Lymphoblastic Leukemia in Remission
  Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

  NCT02141074

  Conditions:   Congenital Bleeding Disorder;   Haemophilia B
  Intervention:   Drug: nonacog beta pegol
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Phase 3 Alogliptin Pediatric Study

  NCT02856113

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Alogliptin Benzoate;   Drug: Placebo
  Sponsor:   Takeda
  Recruiting
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  NCT02521493

  Conditions:   Acute Myeloid Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Cytopenia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
  Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

  NCT03091660

  Conditions:   Stage 0 Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Urothelial Carcinoma
  Interventions:   Biological: BCG Solution;   Biological: BCG Tokyo-172 Strain Solution;   Biological: BCG Tokyo-172 Strain Vaccine;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

  NCT00042289

  Condition:   HIV Infections
  Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
  Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349

  Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
  Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

  NCT03398148

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: risankizumab IV;   Drug: placebo for risankizumab;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

  NCT03398135

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: risankizumab;   Drug: placebo for risankizumab
  Sponsor:   AbbVie
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

  NCT03105128

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  NCT03104413

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
  Sponsor:   AbbVie
  Recruiting
• Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507

  Condition:   Cancer Survivor
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Chronic Hypertension and Pregnancy (CHAP) Project

  NCT02299414

  Condition:   Hypertension
  Interventions:   Drug: Anti-hypertensive therapy;   Other: No anti-hypertensive therapy (unless BP is severe)
  Sponsors:   University of Alabama at Birmingham;   Columbia University;   Drexel University College of Medicine;   Rutgers, The State University of New Jersey;   Lehigh Valley Hospital;   Saint Peters University Hospital;   Christiana Care Health Services;   Washington University School of Medicine;   Duke University;   University of Texas Southwestern Medical Center;   The University of Texas Health Science Center, Houston;   Stanford University;   University of Pennsylvania;   The University of Texas Medical Branch, Galveston;   University of Utah;   Intermountain Health Care, Inc.;   University of California, San Francisco;   Johns Hopkins University;   University of Pittsburgh;   Ochsner Health System;   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI);   WakeMed Health and Hospitals;   San Francisco General Hospital;   McKay-Dee Hospital;   Winthrop University Hospital;   New York Hospital Queens;   Latter Day Saints Hospital;   Lyndon B Johnson General Hospital;   Virtua Medical Group;   Bayview Medical Center;   Duke Regional Hospital;   Utah Valley Regional Medical Center;   Northwestern;   Brown (WIHRI);   Baylor College of Medicine;   Case Western/Metro Health;   Ohio State University;   University of Iowa;   University of California, San Diego;   Indiana University;   Unity Point Health-Meriter Hospital WI;   Weill Medical College of Cornell University;   University of Oklahoma;   Medical University of South Carolina;   Beaumont Hospital;   University of Colorado, Denver;   University of Kansas Medical Center;   Denver Health and Hospital Authority;   Gundersen Health System;   Aurora Health Care;   Oregon Health and Science University;   Medical College of Wisconsin;   Temple University;   New Jersey Medical School;   University of South Alabama;   Vanderbilt University;   University of Arkansas;   Miami Valley Hospital;   Emory University;   St. Luke's Hospital and Health Network, Pennsylvania;   Cleveland Clinic Fairview Hospital;   University of Tennessee Health Science Center;   TriHealth Inc.;   Cleveland Clinic Hillcrest Hospital;   Tulane University;   Yale University;   Arrowhead Regional Medical Center
  Recruiting
• OPsumit USers Registry

  NCT02126943

  Condition:   Pulmonary Arterial Hypertension
  Intervention:   Drug: Opsumit (macitentan)
  Sponsor:   Actelion
  Recruiting
• Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

  NCT03376438

  Conditions:   Atrial Flutter;   Tachycardia, Supraventricular;   Tachycardia, Atrial Ectopic;   Tachycardia, Reciprocating;   Tachycardia Atrial;   Tachycardia, Atrioventricular Nodal Reentry;   Tachycardia, Paroxysmal;   Fetal Hydrops
  Intervention:   Other: Prospective observational cohorts
  Sponsors:   The Hospital for Sick Children;   Labatt Family Heart Centre
  Recruiting
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old

  NCT03199053

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

  NCT03126916

  Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
  Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Ovarian Teratoma;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

  NCT03057054

  Conditions:   Hematopoietic Cell Transplant Recipient;   Malignant Neoplasm
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Lactobacillus plantarum strain 299;   Biological: Lactobacillus plantarum strain 299v;   Other: Placebo
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147

  Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
  Recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  NCT00772200

  Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
  Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

  NCT02766465

  Condition:   Sickle Cell Disease
  Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Hematopoietic Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
  Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program;   Emory University
  Recruiting
• Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  NCT00920972

  Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
  Interventions:   Drug: Treatment Plan 1: Stratum 1;   Drug: Treatment Plan 2: Strata 2, 3, or 4;   Drug: GVHD Regimen A: UCB Recipients;   Drug: GVHD Regimen B: BM Recipients
  Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
  Recruiting
• Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial

  NCT03009110

  Conditions:   Surgical Wound Infection;   Cesarean Section
  Interventions:   Device: Prophylactic NPWT;   Device: Standard Dressing
  Sponsors:   Indiana University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   KCI USA, Inc.
  Recruiting
• Natural History Study Protocol in PMM2-CDG (CDG-Ia)

  NCT03173300

  Condition:   Phosphomannomutase 2 Deficiency
  Intervention:  
  Sponsor:   Glycomine, Inc.
  Recruiting
• Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

  NCT02962765

  Condition:   Hemophilia A
  Intervention:  
  Sponsor:   Octapharma
  Recruiting
• Zoliflodacin in Uncomplicated Gonorrhoea

  NCT03959527

  Condition:   Gonorrhea
  Interventions:   Drug: zoliflodacin;   Drug: ceftriaxone;   Drug: azithromycin
  Sponsor:   Global Antibiotics Research and Development Partnership
  Recruiting
• Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

  NCT03350035

  Conditions:   Status Epilepticus;   Convulsive Status EPILEPTICUS;   Non Convulsive Status Epilepticus;   Epilepsy
  Interventions:   Drug: Ganaxolone;   Drug: Placebo
  Sponsor:   Marinus Pharmaceuticals
  Recruiting
• NeuMoDx PrEDiCTiNG Study Evaluation Plan

  NCT03970850

  Conditions:   Chlamydia Trachomatis Infection;   Neisseria Gonorrheae Infection
  Interventions:   Diagnostic Test: NeuMoDx CT/NG Assay;   Diagnostic Test: FDA-cleared NAATs
  Sponsors:   NeuMoDx Molecular, Inc.;   NAMSA
  Recruiting
• A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

  NCT04104685

  Condition:   Acne Vulgaris
  Interventions:   Combination Product: FCD105;   Drug: 3% Minocycline Foam;   Drug: 0.3% Adapalene Foam;   Other: Vehicle Foam
  Sponsor:   Foamix Ltd.
  Recruiting
• Pulmonary Hypertension Association Registry

  NCT04071327

  Conditions:   Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension;   Pulmonary Hypertension
  Intervention:  
  Sponsors:   Pulmonary Hypertension Association, Inc.;   University of Washington, the Collaborative Health Studies Coordinating Center
  Recruiting
• Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

  NCT03824405

  Condition:   Atopic Dermatitis
  Interventions:   Drug: BTX 1204;   Drug: Vehicle
  Sponsor:   Botanix Pharmaceuticals
  Recruiting
• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

  NCT03417102

  Conditions:   Hemophilia A;   Hemophilia B
  Interventions:   Drug: fitusiran;   Drug: recombinant Factor VIIa and FEIBA
  Sponsor:   Genzyme, a Sanofi Company
  Recruiting
• TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

  NCT03745638

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle cream
  Sponsor:   Incyte Corporation
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03653026

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

  NCT03627767

  Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

  NCT03627091

  Condition:   Crohn's Disease
  Interventions:   Drug: SHP647;   Other: Placebo
  Sponsor:   Shire
  Recruiting
• Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry

  NCT03603275

  Condition:   Hemophilia A
  Intervention:   Drug: Antihemophilic Factor (Kovaltry, BAY81-8973)
  Sponsors:   Bayer;   American Thrombosis and Hemostasis Network
  Recruiting
• Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma

  NCT03595124

  Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Axitinib;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study to Test the Safety of the Investigational Drug Loxo-195 in Children and Adults That May Treat Cancer

  NCT03215511

  Condition:   Solid Tumors Harboring NTRK Fusion
  Intervention:   Drug: BAY2731954
  Sponsor:   Bayer
  Recruiting
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

  NCT03566823

  Condition:   Crohn's Disease
  Interventions:   Biological: SHP647;   Other: Placebo
  Sponsor:   Shire
  Recruiting
• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045

  Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy
  Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy
  Sponsor:   LivaNova
  Recruiting
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

  NCT03493685

  Condition:   Focal Segmental Glomerulosclerosis
  Interventions:   Drug: sparsentan;   Drug: irbesartan
  Sponsor:   Retrophin, Inc.
  Recruiting
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

  NCT03467958

  Condition:   Crohn Disease
  Intervention:   Drug: Ozanimod
  Sponsor:   Celgene
  Recruiting
• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

  NCT03464097

  Condition:   Crohn Disease
  Interventions:   Drug: Ozanimod;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease

  NCT03446001

  Condition:   Alzheimer Disease
  Interventions:   Drug: TRx0237 8 mg/day;   Drug: Placebo;   Drug: TRx0237 16 mg/day
  Sponsor:   TauRx Therapeutics Ltd
  Recruiting
• Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

  NCT03440372

  Condition:   Crohn Disease
  Interventions:   Drug: Ozanimod;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

  NCT03381196

  Condition:   Influenza A
  Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

  NCT03339297

  Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
  Interventions:   Drug: Defibrotide;   Drug: Standard of Care
  Sponsor:   Jazz Pharmaceuticals
  Recruiting
• Fecal Microbiota Transplant National Registry

  NCT03325855

  Conditions:   Fecal Microbiota Transplantation;   Clostridium Difficile Infection;   Gut Microbiome
  Intervention:   Other: None - Observational
  Sponsors:   American Gastroenterological Association;   OpenBiome;   University of California, San Diego;   Icahn School of Medicine at Mount Sinai
  Recruiting
• Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

  NCT03289273

  Condition:   Liver Neoplasms
  Intervention:   Drug: Regorafenib (Stivarga, BAY73-4506)
  Sponsor:   Bayer
  Recruiting
• A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085

  Conditions:   Crohn's Disease;   Ulcerative Colitis
  Interventions:   Drug: 25 mg SHP647;   Drug: 75 mg SHP647
  Sponsor:   Shire
  Recruiting
• Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

  NCT03157128

  Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
  Intervention:   Drug: LOXO-292
  Sponsor:   Loxo Oncology, Inc.
  Recruiting
• DCM Precision Medicine Study

  NCT03037632

  Condition:   Idiopathic Dilated Cardiomyopathy
  Intervention:   Behavioral: Family Heart Talk Booklet
  Sponsors:   Ray Hershberger;   National Heart, Lung, and Blood Institute (NHLBI);   National Human Genome Research Institute (NHGRI)
  Recruiting
• Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

  NCT02931539

  Condition:   Cytomegalovirus (CMV)
  Interventions:   Drug: Maribavir;   Drug: Ganciclovir;   Drug: Valganciclovir;   Drug: Foscarnet;   Drug: Cidofovir
  Sponsor:   Shire
  Recruiting
• Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

  NCT02834793

  Condition:   Lennox-Gastaut Syndrome (LGS)
  Interventions:   Drug: Placebo;   Drug: Perampanel
  Sponsor:   Eisai Inc.
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT02819635

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
  Sponsor:   AbbVie
  Recruiting
• A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

  NCT02815891

  Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

  NCT02783651

  Condition:   Relapsed/Refractory Acute Lymphoblastic Leukemia
  Intervention:   Other: Other
  Sponsor:   Amgen
  Recruiting
• A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

  NCT02663908

  Condition:   Prostate Cancer
  Interventions:   Drug: Degarelix;   Drug: Leuprolide
  Sponsors:   Ferring Pharmaceuticals;   Memorial Sloan Kettering Cancer Center;   Duke Clinical Research Institute
  Recruiting
• ATHN 2: Factor Switching Study

  NCT02546622

  Condition:   Hemophilia
  Interventions:   Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013;   Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
  Sponsors:   American Thrombosis and Hemostasis Network;   Shire;   CSL Behring;   Bioverativ Therapeutics Inc.;   Bayer
  Recruiting
• An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

  NCT02172950

  Conditions:   Hemophilia A;   Severe Hemophilia A
  Intervention:   Biological: rVIII‑SingleChain
  Sponsor:   CSL Behring
  Recruiting
• Prospective Global Registry for the Study of Chronic Total Occlusion Intervention

  NCT02061436

  Condition:   Coronary Artery Disease
  Intervention:  
  Sponsor:   Minneapolis Heart Institute Foundation
  Recruiting
• Registry for Participants With Short Bowel Syndrome

  NCT01990040

  Condition:   Short Bowel Syndrome
  Intervention:  
  Sponsor:   Shire
  Recruiting
• Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  NCT01790152

  Conditions:   Cancer Survivor;   Hodgkin Lymphoma in Remission;   Leukemia in Remission;   Lymphoblastic Lymphoma;   Osteosarcoma;   Recurrent Leukemia;   Recurrent Lymphoma;   Recurrent Malignant Neoplasm
  Interventions:   Other: Assessment of Therapy Complications;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

  NCT01526681

  Condition:   Peripheral Nerve Injuries
  Interventions:   Other: Processed Human Nerve Graft;   Other: Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.;   Other: Autogenous Nerve Graft;   Device: Nerve Tube Conduit;   Procedure: Autologous Breast Reconstruction with Neurotization;   Procedure: Autologous Breast Reconstruction without Neurotization
  Sponsor:   Axogen Corporation
  Recruiting
• Product Surveillance Registry

  NCT01524276

  Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women

  NCT01310023

  Condition:   Antiretroviral Toxicity
  Intervention:  
  Sponsors:   Harvard School of Public Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Mental Health (NIMH);   National Heart, Lung, and Blood Institute (NHLBI);   National Institute on Deafness and Other Communication Disorders (NIDCD);   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   National Institute of Neurological Disorders and Stroke (NINDS);   Tulane University School of Medicine;   National Institute of Dental and Craniofacial Research (NIDCR);   NIH Office of AIDS Research (OAR)
  Recruiting
• Natural History Study of SCID Disorders

  NCT01186913

  Conditions:   Severe Combined Immunodeficiency (SCID);   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis;   ADA SCID;   XSCID
  Intervention:  
  Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium (PIDTC);   Office of Rare Diseases (ORD);   National Center for Advancing Translational Science (NCATS)
  Recruiting
• International Collaborative Gaucher Group (ICGG) Gaucher Registry

  NCT00358943

  Conditions:   Gaucher Disease;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease
  Intervention:  
  Sponsor:   Genzyme, a Sanofi Company
  Recruiting